Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label exploratory study of rhBSSL on fat absorption in cystic fibrosis with pancreatic insufficiency
2007-004063-21Phase 2Completed
- Sponsor
- Sobi
- Start
- Oct 2007
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bucelipase alfa in cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI), sponsored by Sobi. Primary endpoint: Coefficient of Fat Absorption (CFA). Started Oct 2007; status: completed.
02
Drugs
bucelipase alfa
03
Conditions
cystic fibrosis (CF)exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on 2007-004063-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004063-21.